KIDNEY MEDULLARY CARCINOMA
Clinical trials for KIDNEY MEDULLARY CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new KIDNEY MEDULLARY CARCINOMA trials appear
Sign up with your email to follow new studies for KIDNEY MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets bone metastases in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to the standard treatment (cabozantinib) can improve outcomes for people with advanced kidney cancer that has spread to the bone. About 134 participants will receive either the combination or cabozantinib alone. The …
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:55 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like atypical teratoid/rhabdoid tumors or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes, making them hard to tre…
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:54 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…
Matched conditions: KIDNEY MEDULLARY CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 13:54 UTC